Saturday 17 October 2026
Export OGEN’s income statement to Excel — free account
Oragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022. In the quarter to June 2026, EPS grew 81.6% and free cash flow fell 66.4%, each against the same quarter a year earlier.
0.43
0.01
−2.27%
Follow OGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,307.07%) | (311.00%) | (243.94%) | (192.73%) |
+8 more TTM periods Free account |
|
| (264.23%) | (173.03%) | (170.58%) | (121.77%) | ||
ROIC |
0.00% | (8,025.60%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(274.71%) | (158.96%) | (118.85%) | (110.92%) | |
Average Days of Receivables |
— | — | 0.00 | — | |
Free Cash Flow per Share |
(2.30) | (2.17) | (4.29) | (5.40) | |
Free Cash Flow |
(10.21) | (9.33) | (9.25) | (8.43) | |
| Other line items | |||||
Cash ROIC |
(135.47%) | (75.96%) | (55.43%) | (39.70%) | |
Accounts Receivable Turnover |
— | — | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(562.93) | (16.24) | (11.91) | (12.95) | |
Operating CF/Net income |
1.01 | 0.95 | 0.94 | 0.77 | |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.30) | (2.17) | (4.29) | (5.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates